All sponsors

Innovent Biologics (Suzhou) Co. Ltd. $1801.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS36
PHASE 3 / 2-315
RECRUITING18
READOUTS ≤12 MONTHS14
READOUT SLIPPED >6 MO21%

Delay Index: of 19 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Innovent Biologics (Suzhou) Co. Ltd. on the live radar map → 📅 $1801.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
IBI354
NCT05636215
P1/2RecruitingLocally Advanced Unresectable or Metastatic Solid Tumors3682025-04-30
Sintilimab
NCT05280626
P2Not yet recruitingDiffuse Large B-Cell Lymphoma1002025-12-31
IBI363
NCT06281678
P2RecruitingMelanoma; Non-small Cell Lung Cancer1782026-03-01
IBI3014
NCT06974812
P1/2RecruitingUnresectable Locally Advanced or Metastatic Solid Tumors2502026-06-30
IBI362
NCT07469800
P3RecruitingOverweight; Obesity3362026-08-01
IBI362
NCT06937749
P2Active, not recruitingMetabolic Dysfunction-associated Steatohepatitis (MASH)1812026-09-23 (+5 mo)
IBI362
NCT06862908
P2Active, not recruitingObesity; Heart Failure With Preserved Ejection Fraction (HFPEF)1412026-09-24
Tirzepatide
NCT07000955
P1/2Active, not recruitingObesity982026-09-30 (-2 mo)
IBI363+IBI305
NCT07124793
P2Not yet recruitingEGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer602026-09-30
Pemetrexed
NCT05116462
P3Active, not recruitingNon-Small Cell Lung Cancer5062026-09-30 (+37 mo)
IBI3003
NCT06083207
P1/2RecruitingMultiple Myeloma1162026-10-31
Pemetrexed
NCT07122687
P2RecruitingResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer1702026-11-30
G-HOPE-001
NCT06238843
P3Active, not recruitingUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma4642026-12-30 (+7 mo)
IBI363
NCT07402070
P2Not yet recruitingResectable Stage II-III Non-small Cell Lung Cancer102026-12-31
IBI363
NCT06797297
P2Active, not recruitingMelanoma2032026-12-31 (+9 mo)
Dexamethasone
NCT07764861
P2Not yet recruitingMultiple Myeloma1202026-12-31
IBI362
NCT06884293
P3Active, not recruitingOverweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)4792026-12-31
IBI311
NCT07113262
P3RecruitingThyroid Eye Disease1112026-12-31
Aflibercept Ophthalmic
NCT05972473
P3Active, not recruitingNeovascular Age-related Macular Degeneration6002027-02-28
IBI3002
NCT07399067
P2RecruitingAtopic Dermatitis1202027-03-23
IBI362
NCT06931028
P3RecruitingSleep Apnea; Obstructive2602027-05-07
Compound Betamenth Group
NCT07842497
P2RecruitingAcute Gouty Arthritis1322027-05-11
IBI3005
NCT07612137
P1/2Not yet recruitingSolid Tumor2822027-06-30
IBI343
NCT07066098
P3RecruitingPancreatic Cancer2012027-06-30
IBI362
NCT07255209
P3RecruitingAdolescents With Obesity or Overweight With Weight-Related Comorbidities1802027-10-31
Part B -Telitacicept
NCT07836660
P2Not yet recruitingSjögren's Disease1982027-11-01
IBI354
NCT06834672
P3Active, not recruitingOvarian; Primary Peritoneal4502027-12-28
IBI343,Gemcitabine, Albumin-bound Paclitaxel
NCT07483554
P2RecruitingCLDN18.2 Positive; Gastric/Gastroesophageal Junction Adenocarcinoma3892028-03-31
Sintilimab
NCT05890742
P3Active, not recruitingMSI-H4532028-04-15
Dupilumab Injection
NCT07754786
P3RecruitingAtopic Dermatitis5202028-07-01
IBI363
NCT06081920
P2RecruitingMelanoma1802028-10-19 (+40 mo)
IBI363 + bevacizumab
NCT07722494
P3RecruitingColorectal Cancer5502028-10-31
IBI3016
NCT07352969
P2Active, not recruitingHypertension3522029-03-27
Pomalidomide Capsules
NCT07623798
P3RecruitingRelapsed or Refractory Multiple Myeloma2552029-05-31
Oxaliplatin
NCT07917468
P3Not yet recruitingLocally Advanced Rectal Cancer5002030-03-25
IBI343,sintilimab,oxaliplatin,S-1
NCT07483567
P2RecruitingCLDN18.2 Positive; Primary Gastric Adenocarcinoma902030-06-30